ALXO — ALX Oncology Holdings Income Statement
0.000.00%
Last trade - 00:00- $116.93m
- -$27.17m
- 15
- 39
- 11
- 11
Annual income statement for ALX Oncology Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 4.8 | 1.18 | 0 | 0 | 0 |
| Cost of Revenue | |||||
| Gross Profit | 0.436 | 0.107 | — | 0 | — |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 24 | 45.5 | 83.6 | 127 | 170 |
| Operating Profit | -19.2 | -44.3 | -83.6 | -127 | -170 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -19.2 | -45.5 | -83.5 | -123 | -161 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -19.2 | -45.7 | -83.5 | -123 | -161 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -19.2 | -45.7 | -83.5 | -123 | -161 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -23.3 | -50.9 | -83.5 | -123 | -161 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.67 | -2.73 | -2.07 | -3.03 | -3.74 |
| Dividends per Share |